Development of Next-Generation Neoantigen Cancer Vaccine With a Functional Discovery Platform & APC-Targeted LNP System
Time: 11:30 am
day: Day One
Details:
- Overviewing the development of a neoantigen discovery platform that integrates an AI algorithm deeply investigating the characteristics of neoantigens with validated immunogenicity using tumour-specific T cells derived from autologous TILs and PBMCs
- Evaluating delivery via an APC-targeted LNP system, the neoantigen cancer vaccine induced robust antigen-specific T-cell responses and effectively controlled tumours in multiple mouse tumour models
- Discussing an investigator-initiated clinical trial is set to begin in China
